Fruquintinib
Brand Names: Fruzaqla
Methodology & AI Transparency ⓘ
Fruquintinib Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1.
- 2 Real-world patient consensus: Tracked across 8 patient dosage logs with a 84% satisfaction benchmark (RxCUI 2670184).
- 3 Typical cash cost range: Public pharmacy ledger: $24.70 low cash benchmark vs. $60.52 chain retail average ($0.4000/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Fruquintinib): diarrhea (8.5%), abdominal discomfort (4%), nausea (9.2%).
Ask our AI Specialists anything about Fruquintinib
Fruquintinib Mechanism, CYP450 Pathways & DailyMed Monograph
1. Indications and usage fruzaqla: is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy.
12.1. Mechanism of Action Fruquintinib is a small molecule kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 with IC 50 values of 33, 35, and 0.5 nM, respectively. In vitro studies showed fruquintinib inhibited VEGF-mediated endothelial cell proliferation and tubular formation. In vitro and in vivo studies showed fruquintinib inhibited VEGF-induced VEGFR-2 phosphorylation. In vivo studies showed fruquintinib inhibited tumor growth in a tumor xenograft mouse model of colon cancer.
Pharmacokinetic profiling of Fruquintinib demonstrates an elimination half-life of Terminal t½ estimated at 7–19 hrs depending on renal/hepatic reserve (Fruquintinib) with F ≈ 62%–74% systemic availability after standard oral Fruquintinib administration systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across fruquintinib regimens, reaching clinical onset within time to peak concentration spans 1 to 3 hrs under fruquintinib maintenance.
Titration schedules for Fruquintinib (1 mg/1 Capsule → 5 mg/1 Capsule) require excluding contraindications none.; severe drug-induced hypersensitivity to fruquintinib or inactive tablet/vehicle binders; real-world patient logs highlight nausea (9.2% of reports), diarrhea (8.5% of reports), headache (7.4% of reports) alongside a 84.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Fruquintinib (fda prescription therapeutic agent).
Botanical enzyme modulators may alter oral first-pass exposure of Fruquintinib; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS None.
- Severe drug-induced hypersensitivity to Fruquintinib or inactive tablet/vehicle binders
Logged Side-Effect Incidence (8 Reports)
Fruquintinib Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fruquintinib)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Quality-adjusted survival in patients with metastatic colorectal cancer treated: What a 461-Participant Study Found Fruquintinib provides a clinically meaningful quality-adjusted survival benefit versus placebo in refractory mCRC. ESMO open • 2025-03-15 • Phase III Randomized Trial | N = 461 | 93/100 | PMID 39985889 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Additional C-QTc analysis, including only fruquintinib concentrations, showed no relationship between ΔQTcP and fruquintinib concentrations. Journal of clinical pharmacology • 2025-11-15 • Phase III Randomized Trial | N = 137 | 88/100 | PMID 40485075 ↗ |
Fruquintinib Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.4000/unit (~$12.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $60.52 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $24.70 / mo | View logs ↓ |
Fruquintinib Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Fruquintinib RxNorm Concept ID | 2670184 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.4000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $60.52 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $24.70 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Fruquintinib Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Fruquintinib: FDA labeling (2026-07-31, NDC 63020-210), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Fruquintinib community threads and patient logs by age, biological sex, dosage, and treatment duration.